12Aug 2023
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma.

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma.

A study assessed treatment for aggressive Merkel cell carcinoma. Standard care is anti-PD-1/PD-L1 therapy. Patients received combined nivolumab/ipilimumab, with or without SBRT. Results from 50 patients (24 ICI-naive, 26 with previous ICI exposure) showed high response rates (ORR) with first-line treatment (100% ORR in ICI-naive, 31% in previously treated). Comparable ORRs between groups with/without SBRT. Side effects observed in both groups. Combined nivolumab/ipilimumab offers effective and safe first-line and salvage treatment for Merkel cell carcinoma, with SBRT not enhancing efficacy.

  • #oncology

Like

Save

Share